Preventive Cardiology September 24, 2026
How Your Body Ages Impacts Your Heart September 24, 2026
Cardiovascular events often seem to strike suddenly as we age, with some physicians arguing that they’re inevitable. Now a new JAMA Cardiology analysis suggests that the way our bodies age may clue-in cardiovascular trouble earlier than expected.
Cardiovascular Disease Solutions September 21, 2026
ICDs in HCM Patients, A Life Saving Combo September 21, 2026
A new Circulation study just confirmed that implanted cardioverter-defibrillators (ICDs) have saved nearly one in six HCM patients, lending massive support to their continued use.
Pharmaceuticals September 17, 2026
Frailty Doesn’t Factor in Semaglutide Outcomes September 17, 2026
A new secondary analysis of the SELECT trial pushes back on the instinct for avoiding new semaglutide prescriptions in frail patients after finding that the drug delivered its CV benefits regardless of frailty.
Artificial Intelligence September 14, 2026
The Queen Arrives With AI-ECG for Urgent MI September 14, 2026
Many heart attack patients still miss the window for life-saving treatment because of diagnostic delays, but that’s changing with the FDA’s De Novo authorization of Powerful Medical’s Queen of Hearts AI-ECG model that detects STEMI and its harder-to-spot equivalents.
Cardiology Pharmaceuticals September 10, 2026
Novo, Novartis, and How Two Trials Cast Doubt on CVD Biomarkers September 10, 2026
Cardiology just took back-to-back blows to two of its most promising prevention strategies. One drug for lowering lipoprotein(a) and another targeting interleukin-6 both failed in major trials, even as fresh data reaffirms just how much those factors matter.
Cardiogenetics September 10, 2026
Can Polygenic Risk Scores Uncover Hidden CVD? September 10, 2026
It’s rare that one gene causes CVD, just as it’s rare for one CV condition to occur in isolation. In a recent JACC issue, researchers show that […]
Surgeries & Interventions September 3, 2026
A Tale of Two Studies and the Importance of Patient Selection September 3, 2026
Two recent studies are forcing an important conversation in cardiology – some of the field's most common procedures may not be as clearly beneficial as open-label data originally suggests.
Cardiology Pharmaceuticals August 31, 2026
The Full Picture Clarifies Aficamten’s Impact on nHCM August 31, 2026
We are inching closer to a treatment for nonobstructive hypertrophic cardiomyopathy after Cytokinetics presented the full results from the ACACIA-HCM trial, showing that its cardiac myosin inhibitor, MYQORZO (aficamten), meaningfully improves how nHCM patients feel and function.
Cardiology August 27, 2026
Cardiology is Getting Older and Struggling to Keep Up August 27, 2026
Here’s an encouraging factoid –the number of cardiologists in the U.S. rose in the last 20 years. However, a recent JACC study suggests per-capita cardiologist density has actually declined since 2003, and the average cardiologist’s age keeps creeping higher.
Artificial Intelligence August 24, 2026
Context Matters for AI Diagnostic Performance August 24, 2026
With all the talk of AI outperforming and replacing doctors, a new JACC study reminds us – AI diagnostic algorithms don’t perform great when applied to populations different from the ones they’re trained on.
Heart Failure August 21, 2026
TARTAN-HF’s Targeted Tests for Diabetes Patients August 21, 2026
Scans to screen all 40M Americans with diabetes for HF would be nearly impossible, but the TARTAN-HF trial may have found a more streamlined method by leveraging the cardiometabolic connection.
Cardiac Imaging August 20, 2026
No Gadolinium Contrast? No Problem with VNE August 20, 2026
The gold standard for spotting myocardial scarring requires injecting gadolinium contrast during cardiac MRI, which adds time, cost, and a barrier for patients who can't receive it. Now a new study suggests AI may replace that injection in some cases.
Obesity Care August 17, 2026
Just How Bad is BMI at Predicting CVD Risk? August 17, 2026
We all know BMI is pretty useless for predicting CV risk, and a new JACC analysis puts hard numbers on just how much it misses, including a high-risk group hiding in plain sight among "normal weight" patients.
Surgeries & Interventions August 13, 2026
More Interventional Cardiologists, More Low-Value Stents August 13, 2026
The old adage that "built capacity gets used" applies to cardiology too. A Lown Institute study found that regions with the most PCI-performing physicians lead to a disproportionately higher share of patients receiving stents they’re unlikely to benefit from.
Cardiology Business August 10, 2026
iRhythm Expands MCT Footprint with VitalConnect Acquisition August 10, 2026
iRhythm, best known for its Zio cardiac monitoring wearables, is moving to expand well beyond its 14-day-patch roots by acquiring wearable biosensor company VitalConnect for $287.5M.
Cardiology Pharmaceuticals August 6, 2026
ZEUS Tells Us Inflammation Might Not Be the Answer August 6, 2026
Cardiovascular inflammation has been the talk of the town in cardiology, and while Novo Nordisk was wise to pursue treating it, results from the ZEUS trial have led to a thunderous debate on whether or not it ever played a role in ASCVD.
Cardiology August 3, 2026
How to Make Cardiologists Love Academia Again August 3, 2026
Cardiology is one of the most data-driven medical specialties a physician can pursue. So why is the source of that data – cardiac academia – declining in both workforce and prestige?
Cardiology Pharmaceuticals July 31, 2026
Another Look at Attruby Reveals Bolstered Benefits July 31, 2026
As the ATTR-CM market gets more crowded, medications will have to prove their place, and a sub-analysis of the ATTRibute-CM trial shows BridgeBio’s Attruby (acoramidis) has the efficacy to remain competitive.
Structural Heart July 30, 2026
Knowing When to Intervene in Mitral Regurgitation July 30, 2026
A common question in structural heart cardiology is “when do we know to intervene?” and recently released 25-year mitral regurgitation data might just have given us an answer.